PDCD1 and hepatocellular carcinoma: At present, cancer immunotherapies such as immune checkpoint inhibitors (ICIs) (such as anti-PD-1/PD-L1 monoclonal antibody) and CAR-T cell therapy have made breakthroughs in a variety of tumors, but their efficacy in HCC is still limited to a certain extent (11–13).